[Novel Treatment of Multiple System Atrophy in the Era of the New MDS Criteria].
Brain Nerve
; 75(2): 149-156, 2023 Feb.
Article
in Ja
| MEDLINE
| ID: mdl-36750213
ABSTRACT
As our understanding of the pathogenesis of multiple system atrophy (MSA) continues to advance, significant research has focused on the development of disease-modifying therapies. In addition to inhibiting the aggregation of α-synuclein (αS) protein, a major culprit of MSA pathogenesis, disease-modifying drugs have been developed to mitigate cell-to-cell transmission of aggregated αS, thereby suppressing subsequent neuroinflammation, and release of trophic factors. However, most of these therapies have been unsuccessful. The diagnostic criteria for MSA have recently been revised to allow for earlier and more reliable diagnosis. In addition, clear criteria for prodromal MSA have been established, which is expected to narrow the translational gap.
Full text:
1
Database:
MEDLINE
Main subject:
Multiple System Atrophy
Limits:
Humans
Language:
Ja
Year:
2023
Type:
Article